Menora Mivtachim Holdings LTD. lifted its holdings in Allergan PLC. (NYSE:AGN) by 65.8% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 253,215 shares of the company’s stock after buying an additional 100,515 shares during the period. Allergan PLC. comprises 2.1% of Menora Mivtachim Holdings LTD.’s holdings, making the stock its 15th largest holding. Menora Mivtachim Holdings LTD. owned approximately 0.08% of Allergan PLC. worth $51,896,000 as of its most recent SEC filing.
Other institutional investors have also bought and sold shares of the company. Pathstone Family Office LLC increased its holdings in shares of Allergan PLC. by 3,327.3% in the 2nd quarter. Pathstone Family Office LLC now owns 377 shares of the company’s stock worth $2,035,000 after buying an additional 366 shares during the last quarter. Howard Hughes Medical Institute bought a new stake in shares of Allergan PLC. in the 2nd quarter worth about $103,000. Jacobi Capital Management LLC increased its holdings in shares of Allergan PLC. by 4.9% in the 1st quarter. Jacobi Capital Management LLC now owns 472 shares of the company’s stock worth $112,000 after buying an additional 22 shares during the last quarter. JNBA Financial Advisors increased its holdings in shares of Allergan PLC. by 2.5% in the 1st quarter. JNBA Financial Advisors now owns 487 shares of the company’s stock worth $116,000 after buying an additional 12 shares during the last quarter. Finally, Massey Quick & Co. LLC increased its holdings in shares of Allergan PLC. by 334.8% in the 2nd quarter. Massey Quick & Co. LLC now owns 500 shares of the company’s stock worth $122,000 after buying an additional 385 shares during the last quarter. Hedge funds and other institutional investors own 82.02% of the company’s stock.
Allergan PLC. (AGN) traded up 3.8813% during midday trading on Wednesday, hitting $184.1088. 6,984,337 shares of the stock traded hands. The company’s 50-day moving average is $202.46 and its 200 day moving average is $227.37. The firm has a market cap of $61.55 billion, a P/E ratio of 5.6093 and a beta of 1.15. Allergan PLC. has a 12-month low of $169.64 and a 12-month high of $256.80.
Allergan PLC. (NYSE:AGN) last posted its quarterly earnings data on Wednesday, November 1st. The company reported $4.15 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $4.06 by $0.09. Allergan PLC. had a net margin of 79.17% and a return on equity of 7.37%. The business had revenue of $4.03 billion during the quarter, compared to analyst estimates of $4.04 billion. During the same quarter last year, the firm posted $3.32 earnings per share. The business’s revenue for the quarter was up 11.4% compared to the same quarter last year. On average, analysts anticipate that Allergan PLC. will post $16.21 EPS for the current fiscal year.
Allergan PLC. declared that its board has approved a stock buyback plan on Monday, September 25th that allows the company to repurchase $2.00 billion in shares. This repurchase authorization allows the company to buy up to 2.8% of its shares through open market purchases. Shares repurchase plans are usually an indication that the company’s board believes its stock is undervalued.
The firm also recently disclosed a quarterly dividend, which will be paid on Friday, December 15th. Stockholders of record on Friday, November 17th will be paid a $0.70 dividend. This represents a $2.80 annualized dividend and a dividend yield of 1.58%. The ex-dividend date of this dividend is Thursday, November 16th. Allergan PLC.’s payout ratio is 9.95%.
A number of research firms recently commented on AGN. Wells Fargo & Company reaffirmed an “outperform” rating and set a $280.00 price target (up from $270.00) on shares of Allergan PLC. in a research note on Wednesday, August 9th. Cantor Fitzgerald set a $231.00 price target on shares of Allergan PLC. and gave the stock a “hold” rating in a research note on Wednesday. UBS AG reaffirmed an “outperform” rating and set a $275.00 price target on shares of Allergan PLC. in a research note on Wednesday, August 9th. Piper Jaffray Companies set a $227.00 price target on shares of Allergan PLC. and gave the stock a “hold” rating in a research note on Friday, October 13th. Finally, BidaskClub cut shares of Allergan PLC. from a “buy” rating to a “hold” rating in a research note on Wednesday, August 9th. One equities research analyst has rated the stock with a sell rating, eleven have assigned a hold rating and twelve have given a buy rating to the company. Allergan PLC. presently has an average rating of “Hold” and a consensus price target of $252.52.
TRADEMARK VIOLATION WARNING: “Menora Mivtachim Holdings LTD. Boosts Stake in Allergan PLC. (AGN)” was originally reported by Community Financial News and is owned by of Community Financial News. If you are viewing this article on another publication, it was stolen and republished in violation of US and international trademark and copyright laws. The correct version of this article can be viewed at https://www.com-unik.info/2017/11/01/menora-mivtachim-holdings-ltd-boosts-stake-in-allergan-plc-agn.html.
Allergan PLC. Profile
Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.
Want to see what other hedge funds are holding AGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Allergan PLC. (NYSE:AGN).
What are top analysts saying about Allergan PLC.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Allergan PLC. and related companies.